Below is a look at some of the headlines for companies that made news in the healthcare sector on May 16, 2012.
Newly discovered biomarkers could provide physicians with information that will aid in the diagnosis and treatment of disease. The big question for investors is whether, in light of the recent Supreme Court ruling Mayo Collaborative Services Inc. v. Prometheus Laboratories, companies will be able to profit from that innovation.
Goldman Sachs upgrades Incyte (NASDAQ: INCY) from Neutral to Buy with a price target of $29 (up from $21), suggesting a 26% premium from today's prices as the drug discovery company focused on developing proprietary small molecule drugs becomes the latest M&A target.
In an exclusive interview with Liz Cermak, Executive Vice President and Chief Commercial Officer of POZN, we discuss the implications of a European licensing deal for their migrane drug MT 400.
about 5 hours ago
Medtronic Receives Notification of Activities Relating to INFUSE Bone Graft; FDA Receives Repros' Submission And... http://t.co/vTjySscD
about 18 hours ago
OraSure In-Home HIV Test Kit Moves Closer to FDA Approval http://t.co/3apZYJHb
about 18 hours ago
USA boosts Alzheimer's funding as prevention trial is launched: http://t.co/6HGiQuIu
about 18 hours ago
How payers, pharmas are experimenting with outcomes based reimbursement http://t.co/aV10VjPJ
about 19 hours ago
Will Mayo v. Prometheus Fire Up Pharma?: Kevin DeGeeter: Newly discovered biomarkers could provide physicians wi... http://t.co/doXumsu8
about 1 day ago
Sugar makes you stupid: Study shows high-fructose diet sabotages learning, memory http://t.co/TuGuFq1F
about 1 day ago
'Fat tax' - http://t.co/8M5qcfp0
about 1 day ago
Nice approves prostate cancer drug - Health News - Health & Families - The Independent http://t.co/A8HSYzEd
Free Phone Trade Alerts
